Faculty profile

Angela Genge

ResearcherNeurology and NeurosurgeryMcGill University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses may be missing. Find their university profile.

Angela Genge

Researcher

Neurology and Neurosurgery

McGill University

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
72 publications in the last five years, latest in 2026.
Senior (last) author on 9 recent papers, a sign of leading a research group.
Principal investigator on 2 research grants (2 CIHR), most recently in 2016.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

110

Publications

212

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Amyotrophic Lateral Sclerosis (Als)Csf Enoxacin Mirna Pharmacodynamics Pharmacokinetics Phase 1 Clinical Trial Rare Disease

Latest papers

Phase 3b Extension Study MT‐1186‐A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis
Muscle and Nerve · 2026 · first author
A changed landscape: five-year retrospective on the paradigm shift in genetic testing practices for ALS in Canada
European Journal of Human Genetics · 2026
Types and frequencies of adverse events across clinical trials for patients with amyotrophic lateral sclerosis: an analysis of the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database.
Amyotrophic lateral sclerosis & frontotemporal degeneration · 2026

All 110 publications

Latest funding

Unifying Molecular Omics, Multi-Modal Neuroimaging and Artificial Intelligence for Biologically-defined Patient Stratification in Amyotrophic Lateral Sclerosis
CIHR · 2021 · Co-investigator
$698,064
Workshop to CAPTURE ALS
CIHR · 2019 · Co-investigator
$20,000
REALS: Testing the safety of repurposed Enoxacin for the treatment of Amyotrophic Lateral Sclerosis
CIHR · 2016 · Nominated PI
$256,250

All 6 grants and awards

110 publications.

Phase 3b Extension Study MT‐1186‐A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis

Genge A, Rothstein J, De Silva S, Zinman L, Chum M, Chiò A, Sobue G, Aoki M, Yoshino H, Doyu M

Muscle and Nerve20261 citationsFirst author

DOI: 10.1002/mus.70120

A changed landscape: five-year retrospective on the paradigm shift in genetic testing practices for ALS in Canada

Binet M, Jewett G, Breiner A, Chum M, Genge A, Schellenberg K, Shoesmith C, Pfeffer G, Salmon K

European Journal of Human Genetics2026

DOI: 10.1038/s41431-026-02171-1

Types and frequencies of adverse events across clinical trials for patients with amyotrophic lateral sclerosis: an analysis of the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database.

Kim S, Curtis SE, Iacono D, Mehdiyoun NF, Mitchell L, Genge A, Brandt AU, Pooled Resource Open-Access ALS Clinical Trials Consortium, Mancini M

Amyotrophic lateral sclerosis & frontotemporal degeneration2026

DOI: 10.1080/21678421.2026.2667290 PMID: 42160473

Heterogeneity in the Analysis of the ALSFRS-R in ALS Clinical Trials and its Effect on the Validity and Precision of Trial Conclusions.

Weemering DN, van Unnik JWJ, Genge A, van den Berg LH, van Eijk RPA

Neurology2026

DOI: 10.1212/wnl.0000000000214937 PMID: 42013406

A prospective, multi-center, observational study of the safety, tolerability and effectiveness of Nusinersen in adult patients with spinal muscular atrophy.

Zaidman CM, Proud C, Liao B, Rad N, Ho D, Chu ML, Ladha S, Crawford TO, Nayar S, Genge A, Frey M, Heatwole C, Lew D

Neuromuscular disorders : NMD2026

DOI: 10.1016/j.nmd.2025.106256 PMID: 41813449

Opportunities and challenges related to participant stratification and cohort enrichment in ALS clinical trials.

Yusuf S, Allen MD, Kang H, Phillips DE, Genge A

Amyotrophic lateral sclerosis & frontotemporal degeneration2026Senior author

DOI: 10.1080/21678421.2026.2659128 PMID: 42033202

The World Federation of Neurology Specialty Group in ALS/MND: toward strategic partnership and new frontiers.

Kiernan MC, Genge A, Grosskreutz J, Kuwabara S, Lillo P, Rosenfeld J, Cummings C

Amyotrophic lateral sclerosis & frontotemporal degeneration2026

DOI: 10.1080/21678421.2026.2663915 PMID: 42060866

Safety of Intravenous Edaravone in Clinical Practice.

Genge A, Apple S

Muscle & nerve2026First author

DOI: 10.1002/mus.70038 PMID: 41653005

ALS motor phenotypes: a revised 'OPM' classification.

Meyer T, Ticozzi N, Weber M, Ravits J, Lingor P, Kuźma-Kozakiewicz M, Boentert M, Grehl T, Corcia P, Povedano Panadés M, Maier A, Ingre C, Cetin H, Weydt P, Lunetta C, van den Berg L, Ludolph AC, Brenner D, Turner MR, Genge A

Amyotrophic lateral sclerosis & frontotemporal degeneration2026Senior author

DOI: 10.1080/21678421.2026.2644277 PMID: 41843813

Utility of patient subgrouping in ALS clinical trials: a World Federation of Neurology white paper.

Rosenfeld J, Abrahams S, McHutchinson C, Ajroud-Driss S, Weber M, Paganoni S, Mitsumoto H, Genge A, Grosskreutz J, Van Den Berg L, Andrews J, Kiernan MC

Amyotrophic lateral sclerosis & frontotemporal degeneration2026

DOI: 10.1080/21678421.2025.2593308 PMID: 41361897

Unifying Molecular Omics, Multi-Modal Neuroimaging and Artificial Intelligence for Biologically-defined Patient Stratification in Amyotrophic Lateral Sclerosis

Co-investigatorCIHR2021Project Grant

Principal investigators: Iturria Medina, Yasser; Kalra, Sanjay

Keywords: Artificial Intelligence; Identifying Disease Stages And Variants; Molecular Omics And Multi-Modal Brain Imaging; Open-Access Data And Software; Personalized Medicine In Amyotrophic Lateral Sclerosis (Als); Precision In Daily Clinical Practice

$698,064

Workshop to CAPTURE ALS

Co-investigatorCIHR2019Planning and Dissemination Grant - Institute Community Support

Principal investigators: Kalra, Sanjay

Keywords: Amyotrophic Lateral Sclerosis; Workshop

$20,000

REALS: Testing the safety of repurposed Enoxacin for the treatment of Amyotrophic Lateral Sclerosis

Nominated PICIHR2016Team Grant: E-Rare Joint Transnational Call

Principal investigators: Genge, Angela L

Keywords: Amyotrophic Lateral Sclerosis (Als); Csf; Enoxacin; Mirna; Pharmacodynamics; Pharmacokinetics; Phase 1 Clinical Trial; Rare Disease; Safety; Tolerability

$256,250

The Canadian Neuromuscular Network (CAN-NMD)

Principal investigatorCIHR2013Network Catalyst Grant: Skeletal Muscle Research

Principal investigators: Korngut, Lawrence W; Campbell, Craig Gordon N; Gagnon, Cynthia; Genge, Angela L; Jasmin, Bernard J; Kothary, Rashmi K; Mah, Jean K; McMillan, Hugh J; Nicolle, Michael W; Warman Chardon, Jodi; Yokota, Toshifumi

Keywords: Clinical Care; Education; Neuromuscular Disease Research Network; Research

$575,614

Magnetic resonance imaging biomarkers in ALS

Co-investigatorCIHR2012Operating Grant

Principal investigators: Kalra, Sanjay

Keywords: Aging; Amyotrophic Lateral Sclerosis; Brain; Cognitive Impairment; Diffusion Tensor Imaging; Magnetic Resonance Imaging; Neurodegeneration

$841,747

The George Karpati Symposium on Neuromuscular Disease: Innovation and Application

Co-investigatorCIHR2009Meetings, Planning and Dissemination Grant: Musculoskeletal Health and Arthritis

Principal investigators: Hastings, Kenneth E

Keywords: Genetic Disorders; Neuromuscular

$6,465

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Angela Genge

Research

Latest papers

Latest funding

Phase 3b Extension Study MT‐1186‐A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis

A changed landscape: five-year retrospective on the paradigm shift in genetic testing practices for ALS in Canada

Types and frequencies of adverse events across clinical trials for patients with amyotrophic lateral sclerosis: an analysis of the Pooled Resource Open-Access ALS Clinical Trials&#xa0;(PRO-ACT) database.

Heterogeneity in the Analysis of the ALSFRS-R in ALS Clinical Trials and its Effect on the Validity and Precision of Trial Conclusions.

A prospective, multi-center, observational study of the safety, tolerability and effectiveness of Nusinersen in adult patients with spinal muscular atrophy.

Opportunities and challenges related to participant stratification and cohort enrichment in ALS clinical trials.

The World Federation of Neurology Specialty Group in ALS/MND: toward strategic partnership and new frontiers.

Safety of Intravenous Edaravone in Clinical Practice.

ALS motor phenotypes: a revised 'OPM' classification.

Utility of patient subgrouping in ALS clinical trials: a World Federation of Neurology white paper.

Unifying Molecular Omics, Multi-Modal Neuroimaging and Artificial Intelligence for Biologically-defined Patient Stratification in Amyotrophic Lateral Sclerosis

Workshop to CAPTURE ALS

REALS: Testing the safety of repurposed Enoxacin for the treatment of Amyotrophic Lateral Sclerosis

The Canadian Neuromuscular Network (CAN-NMD)

Magnetic resonance imaging biomarkers in ALS

The George Karpati Symposium on Neuromuscular Disease: Innovation and Application

Frequent collaborators

Lawrence Korngut

Sanjay Kalra

Richard Frayne

Yana Yunusova

Christian Beaulieu

Jason Karamchandani

Craig Campbell

Marvin Chum

Gerald Pfeffer

Maryam Oskoui

Alan Wilman

John Turnbull

Benjamin Ritsma

Simon Graham

Russell Greiner

Ekaterina Rogaeva

Jodi Warman Chardon

Jasna Kriz

Janice Robertson

Alain Dagher

Lorne Zinman

Bernard Brais

Mahsa Dadar

Jean-Baptiste Poline

Hans Katzberg

Julien Doyon

Janelle Drouin-Ouellet

David Taylor

Esther Fujiwara

Thomas Durcan

Yasser Iturria Medina

Madeleine Sharp

Azadeh Yadollahi

Oury Monchi

Mark Tarnopolsky

Ashley Waito

Michel Panisset

Christine Vande Velde

Dean Eurich

Alan Evans

Types and frequencies of adverse events across clinical trials for patients with amyotrophic lateral sclerosis: an analysis of the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database.